Business & Regulation

Nick Crabb explains the UK’s health technology assessment agency's (NICE's) approach to cell and gene therapies.

If you or your supplier are working with animal-derived components, you run the risk of exposing patients to dangerous contaminations.

Regardless of how Britain leaves the European Union, the global pharma industry must always lobby for positive change.

Why the CVS-Aetna merger could be a transformative event for the pharmaceutical industry.

EFPIA figures give a snapshot of drug development and innovation in Europe. Check out our infographic for some of the key stats.

No-deal Brexit poses unique challenges for the development and advanced therapy sectors, not least tight timelines and a limited ability to stockpile.

The Chinese pharmaceutical market is already more advanced than many in the West imagine – and it only looks set to go in one direction.

Gene therapy deals, clinical trials transparency and sartan medicine reviews… what’s new for pharma in business?

What did the partial government shutdown mean for the US pharma industry?

With the US back to divided government, the US pharma industry could be the number one target for politicians.